Quarterly Activities/Appendix 4C Cash Flow Report

Jul 26, 2026 at 10:15 PM EDT · Issued by Arovella Therapeutics Limited via ASX

Filed with ASX · Jul 26, 2026 at 10:15 PM EDT · 11 pages · English

On 6ix: 6ix.com/news/quarterly-activitiesappendix-4c-cash-flow-report-735

Release

ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 Corporate One, 84 Hotham Street, Preston, VIC 3072 Australia Telephone: + 61 3 9863 6472 investor@arovella.com | www.arovella.com ASX Release 27 July 2026 APPENDIX 4C: FOURTH QUARTER FY26 Highlights for the...

Arovella Therapeutics Limited on 6ix

Earlier from Arovella Therapeutics

Arovella Appoints Acting CEOMay 6
Board Refresh and CEO ResignationMay 4
CLDN18.2 CAR iNKT Cell Preclinical Data UpdateMar 31
Half Year Report and Appendix 4DFeb 19
ALA's ind for ALA-101 accepted by the U.S.FDAJan 28

Later from Arovella Therapeutics

Investor Webinar RegistrationAug 11
Investor Webinar PresentationAug 11
Notification regarding unquoted securities - ALAAug 16
Appendix 4E and Annual ReportAug 19
Appendix 4GAug 19

All Arovella Therapeutics news releases

Follow Arovella Therapeutics into a list and get an email when it puts out news.

Follow Arovella Therapeutics